Expert Review of Anticancer Therapy最新文献_第8页

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine. 转移性前列腺癌反应的预测性生物标志物：为精准医学的新时代铺平道路。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-02 DOI: 10.1080/14737140.2026.2695214

Chiara Mercinelli, Fabrizio Di Costanzo, Christoph Oing, Gualtiero Guandalini, Brigida Anna Maiorano, Enrico Sammarco, Alessia Salfi, Debora Serafin, Valentina Tateo, Antonio Cigliola, Michela Piacentini, Giovanni Luigi Pastorino, Luca Galli, Vincenza Conteduca, Luigi Formisano, Pasquale Rescigno, Andrea Necchi

{"title":"Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.","authors":"Chiara Mercinelli, Fabrizio Di Costanzo, Christoph Oing, Gualtiero Guandalini, Brigida Anna Maiorano, Enrico Sammarco, Alessia Salfi, Debora Serafin, Valentina Tateo, Antonio Cigliola, Michela Piacentini, Giovanni Luigi Pastorino, Luca Galli, Vincenza Conteduca, Luigi Formisano, Pasquale Rescigno, Andrea Necchi","doi":"10.1080/14737140.2026.2695214","DOIUrl":"10.1080/14737140.2026.2695214","url":null,"abstract":"Introduction: The therapeutic landscape for metastatic prostate cancer has expanded substantially over the last decade, yet treatment selection remains predominantly driven by clinical parameters rather than validated molecular predictors. This review addresses the urgent need to refine patient stratification by critically examining emerging and established predictive biomarkers that may enable a precision medicine approach in advanced disease.Areas covered: This review provides a comprehensive overview of predictive biomarkers in metastatic prostate cancer, including androgen receptor aberrations, mismatch repair deficiency, SPOP mutations, TMPRSS2/ERG fusions, PTEN/PI3K/AKT pathway alterations, and novel therapeutic targets such as STEAP1, DLL3, TROP-2, and Nectin-4. We discuss their biological underpinnings, mechanistic relevance, and clinical evidence supporting their potential predictive role across treatment settings. A structured literature search was conducted using PubMed/MEDLINE and major international oncology congress databases, focusing on peer-reviewed publications and clinical trial reports published up to February 2026, with particular emphasis on prospective and biomarker-driven studies.Expert opinion: While several molecular alterations show compelling biological rationale and encouraging clinical signals, few biomarkers have achieved prospective validation sufficient for routine implementation. The next phase of progress will depend on biomarker-enriched trial designs, harmonized testing strategies, and integration of multi-omic profiling to overcome biological heterogeneity and therapeutic resistance.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-15"},"PeriodicalIF":3.0,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO). luminate -101-马卡比：以色列健康维护组织（HMO）对非鳞状转移性非小细胞肺癌患者的治疗模式和临床结果的真实世界研究。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-05-18 DOI: 10.1080/14737140.2026.2671251

Sarah Sharman Moser, Alona Zer, Andre Hejazi, Netta Passwell, Moshe Hoshen, Amin Virani, Simon Sharmokh, Nathalie Daaboul, Sivan Gazit, Jair Bar

{"title":"LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO).","authors":"Sarah Sharman Moser, Alona Zer, Andre Hejazi, Netta Passwell, Moshe Hoshen, Amin Virani, Simon Sharmokh, Nathalie Daaboul, Sivan Gazit, Jair Bar","doi":"10.1080/14737140.2026.2671251","DOIUrl":"10.1080/14737140.2026.2671251","url":null,"abstract":"Background: Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2L+) patients with non-AGA non-squamous (NSQ) metastatic NSCLC (mNSCLC) at a Health Maintenance Organization in Israel.Methods: A retrospective cohort study used de-identified data from the Maccabi Healthcare Services database to identify 2L+ adult patients with non-AGA NSQ mNSCLC between January 2017 and December 2020. Outcomes included progression-free survival (PFS), overall survival (OS), and time-to-next-treatment or death (TTNTD), analyzed using descriptive statistics and Kaplan-Meier methodology.Results: Among 176 2L+ patients, median age was 67 years, 66.5% were male, 51.7% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and 30.7% received third-line therapy. Anti-programmed death-receptor/ligand 1 (anti-PD-[L]1) was the most common 2L therapy (n = 74, 42.0%) following 1L chemotherapy. Median overall TTNTD from 2L initiation was 3.73 months (docetaxel: 1.78 months; anti-PD-[L]1 combination: 7.05 months). Median overall PFS was 2.56 months (docetaxel: 1.78 months; anti-PD-[L]1 combination: 9.48 months) and median overall OS was 5.51 months (docetaxel: 1.81 months; anti-PD-[L]1 combination: 9.48 months).Conclusions: These findings highlight the high unmet need among 2L+ non-AGA NSQ mNSCLC patients in Israel.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"961-969"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer. 肾素-血管紧张素系统抑制剂对纳武单抗治疗转移性非小细胞肺癌临床结果的影响。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-11 DOI: 10.1080/14737140.2026.2615853

Emel Mutlu Ozkan, Ibrahim Karadağ, Elif Sahın, Ayse Nuransoy Cengiz, Muhammet Cengız, Deniz Can Guven, Oktay Bozkurt, Mevlüde Inanç, Metin Ozkan, Umut Kefelı, Devrim Cabuk, Mustafa Erman, Saadettin Kılıckap, Tolga Kosecı, Duygu Bayır, Hacer Demir, Sedat Yıldız, Muslih Urun, Teoman Sakalar, Nargiz Majidova, Cengiz Akosman, Mustafa Ersoy, Pervin Can Sancı, Erdem Kolemen, Gözde Agdas, Erkam Kocaaslan, Ezgi Turkoğlu, Sedat Yıldırım, Berrak Mermıt Ercek, Anıl Karakayalı, Hayati Arvas, Mehmet Mutlu Kıdı, Sedat Biter, Havva Yesıl Cınkır, Latif Karahan, Aslihan Ezgi Apaydın Rollas

{"title":"Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer.","authors":"Emel Mutlu Ozkan, Ibrahim Karadağ, Elif Sahın, Ayse Nuransoy Cengiz, Muhammet Cengız, Deniz Can Guven, Oktay Bozkurt, Mevlüde Inanç, Metin Ozkan, Umut Kefelı, Devrim Cabuk, Mustafa Erman, Saadettin Kılıckap, Tolga Kosecı, Duygu Bayır, Hacer Demir, Sedat Yıldız, Muslih Urun, Teoman Sakalar, Nargiz Majidova, Cengiz Akosman, Mustafa Ersoy, Pervin Can Sancı, Erdem Kolemen, Gözde Agdas, Erkam Kocaaslan, Ezgi Turkoğlu, Sedat Yıldırım, Berrak Mermıt Ercek, Anıl Karakayalı, Hayati Arvas, Mehmet Mutlu Kıdı, Sedat Biter, Havva Yesıl Cınkır, Latif Karahan, Aslihan Ezgi Apaydın Rollas","doi":"10.1080/14737140.2026.2615853","DOIUrl":"10.1080/14737140.2026.2615853","url":null,"abstract":"Background: The objective of this study is to evaluate the correlation between survival outcomes and renin angiotensin system inhibitors (RASI) use in patients treated nivolmab with metastatic non-small cell lung cancer (mNSCLC).Methods: This retrospective cohort multicentre study was conducted on patients with mNSCLC patients treated Nivolumab monotherapy as second line therapy. Factors affecting the survival of patients receiving concurrent RASI therapy with nivolumab were analyzed.Results: 614 patients were included. A total of 288 patients (46.9%) were using concurrent RASI. Patients using RASIs had a median progression free survival (PFS) of 10 months compared to 7 months in non-users. In the multivariate analysis, RASI use (HR: 0.747, 95% CI: 0.594-0.941; p: 0.013) was associated with improved PFS. RASI use was also significantly associated with overall survival (OS), median OS of 20 months in users and 12 months in non-users. In the multivariate analysis, RASI use (HR: 0.600, 95% CI: 0.458-0.787; p < 0.001) was associated with improved OS.Conclusions: In this multicenter real-world study of patients with mNSCLC receiving second-line nivolumab, concomitant use of RASIs was associated with PFS and OS. The integration of RAS blockade into immunotherapy regimens could represent a promising strategy to enhance treatment efficacy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"929-936"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas. Razoxane作为放射增敏剂用于软组织肉瘤的治疗。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-29 DOI: 10.1080/14737140.2026.2623045

John Rothman

{"title":"Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas.","authors":"John Rothman","doi":"10.1080/14737140.2026.2623045","DOIUrl":"10.1080/14737140.2026.2623045","url":null,"abstract":"Introduction: Razoxane, discovered in the 1960s, was evaluated as a topoisomerase II inhibitor to treat cancer. Cancer therapeutic models of the mid-1900's were based on the following three assumptions: treatment agents should demonstrate activity as a single agent, should reduce tumor size, or could exacerbate tumor hypoxia. Razoxane fulfilled none of these requirements.Areas covered: Although well-tolerated, safe, and approved for cancer treatment, Razoxane lacks the cell-killing activity exhibited by other agents and was a commercial failure. It blocks the cell cycle at G2/M boundary, leading to cell cycle synchrony where radiation and chemotherapeutics are most effective. Daughter chromatid separation is inhibited; metaphase clefts do not form; and cells continue to synthesize DNA and become polyploidal, polynucleate, and hypertrophic, demonstrating a senescent phenotype where weakened cells are removed. Cell proliferation halts, allowing neovasculature to mature with structured endothelial lining and reduced sinusoids, thus eliminating a major route by which tumor cells enter the bloodstream and metastasize.Expert opinion: Blockade of the cell cycle at G2/M maximizes DNA alteration in response to therapy; improved oxygenation enhances the generation of reactive oxygen species during polytherapy; and increased vascularity facilitates synergy with radiation and chemotherapy by improving drug delivery.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"891-903"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer genome profiling in sarcomas: current status and future perspectives in Japan. 肿瘤基因组谱分析在日本的现状和未来展望。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-02-11 DOI: 10.1080/14737140.2026.2617407

Tatsusnori Shimoi, Shosuke Kita, Kan Yonemori

{"title":"Cancer genome profiling in sarcomas: current status and future perspectives in Japan.","authors":"Tatsusnori Shimoi, Shosuke Kita, Kan Yonemori","doi":"10.1080/14737140.2026.2617407","DOIUrl":"10.1080/14737140.2026.2617407","url":null,"abstract":"Introduction: Sarcomas are rare, molecularly diverse malignancies that challenge accurate diagnosis and effective therapy. Japan has implemented nationwide comprehensive cancer genomic profiling (CGP) since 2019, creating an integrated framework that enables precision oncology in routine care.Areas covered: This review synthesizes the status of cancer genomic medicine in Japan, delineates the genomic landscape of sarcomas, and summarizes clinically actionable alterations. We describe the diagnostic value of CGP - particularly the contribution of RNA sequencing for fusion detection - and outline national infrastructures (expert panels, registries) and platform trials that operationalize genome-matched therapy access. We also examine emerging directions, including liquid biopsy, multi-omics integration, whole-genome approaches, and artificial intelligence, and discuss practical barriers (tissue quality, turnaround time, drug access) with potential solutions.Expert opinion: Japan's coordinated model - CGP embedded in care, centralized data, and adaptive trial platforms - offers a blueprint for rare cancer precision medicine. Over the next five years, earlier CGP use, broader RNA-enabled diagnostics, and trial-mediated access to targeted agents should expand; coupling liquid biopsy with multi-omics and AI will refine classification and treatment selection. Addressing access and implementation gaps will be critical to translate genomic insights into better outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"829-845"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of tenosynovial giant cell tumor: approved and investigational therapies. 腱鞘巨细胞瘤的治疗：已批准和正在研究的治疗方法。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-24 DOI: 10.1080/14737140.2026.2620510

Alexander P Conway, Andrew Lim, Brian C Schulte, Mark Agulnik

{"title":"Management of tenosynovial giant cell tumor: approved and investigational therapies.","authors":"Alexander P Conway, Andrew Lim, Brian C Schulte, Mark Agulnik","doi":"10.1080/14737140.2026.2620510","DOIUrl":"10.1080/14737140.2026.2620510","url":null,"abstract":"Introduction: Tenosynovial giant cell tumor (TGCT) is a rare, benign neoplasm driven by overexpression of colony-stimulating factor 1 (CSF-1), which recruits CSF-1 receptor (CSF-1 R)-bearing macrophages and other inflammatory cells to promote tumor formation. While surgery remains the first-line treatment for TGCT, many patients experience unresectable or recurrent disease with high morbidity, highlighting the need for effective systemic treatments.Areas covered: This review summarizes the molecular pathogenesis, diagnostic approach, and evolving systemic treatment landscape for TGCT, with a focus on treatments directed at CSF-1/CSF-1 R inhibition. Relevant literature published between 2005 and 2025 was identified through PubMed searches and manual review of reference lists. Clinical efficacy and safety data for approved and investigational CSF-1/CSF-1 R inhibitors, including pexidartinib, vimseltinib, and emerging agents, are discussed.Expert opinion: Pexidartinib and vimseltinib demonstrate comparable efficacy in TGCT with objective response rates (ORR) of 39% and 40%, respectively, at week 25 of treatment; however, vimseltinib offers improved hepatic safety and tolerability, supporting its use as the preferred first-line systemic therapy. Emerging agents, including pimicotinib and emactuzumab, show potential for higher response rates and favorable safety profiles and may further reshape the TGCT treatment paradigm pending phase 3 trial results.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"881-889"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulatory landscape for CAR-T therapy development in the Brazilian context. 巴西car-t疗法发展的监管环境。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-21 DOI: 10.1080/14737140.2026.2617956

Felipe Pantoja Mesquita, Marília Silveira Maia, Pedro Filho Noronha Souza, Luany Elvira Mesquita Carvalho, Luciana Maria de Barros Carlos, Fernando Barroso Duarte

{"title":"Regulatory landscape for CAR-T therapy development in the Brazilian context.","authors":"Felipe Pantoja Mesquita, Marília Silveira Maia, Pedro Filho Noronha Souza, Luany Elvira Mesquita Carvalho, Luciana Maria de Barros Carlos, Fernando Barroso Duarte","doi":"10.1080/14737140.2026.2617956","DOIUrl":"10.1080/14737140.2026.2617956","url":null,"abstract":"Introduction: Chimeric antigen receptor T (CAR-T) therapy represents a significant advance in the treatment of hematologic malignancies, yet its global implementation remains limited by regulatory, logistical, and manufacturing challenges. Understanding differences among international regulatory frameworks is essential for expanding safe and equitable access, particularly in emerging academic programs.Areas covered: This review examines the regulatory pathways, manufacturing requirements, and quality standards governing CAR-T therapies in Brazil, comparing them with those in the United States and the European Union. A focused literature search encompassed peer-reviewed articles, institutional guidelines, and regulatory documents from 2016 to 2025. Key elements assessed include GMP expectations, analytical method validation, biosafety considerations, and infrastructure requirements. The analysis also explores expanded-access mechanisms and summarizes clinical experiences that have used these pathways in the real world.Expert opinion: Despite structural differences, all jurisdictions converge on core principles emphasizing product quality, long-term safety, and traceability. However, Brazil faces unique multi-agency coordination requirements and infrastructural constraints that may delay national deployment. Global evidence indicates that strengthening GMP facilities, analytical validation strategies, and harmonized regulatory processes, particularly for academic and point-of-care manufacturing, will be crucial to broaden access and sustain innovation in CAR-T therapies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"847-864"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Body composition and physical activity as predictors of immune-related adverse events in patients undergoing cancer immunotherapy: a systematic review. 在接受癌症免疫治疗的患者中，身体成分和身体活动作为免疫相关不良事件的预测因素：一项系统综述。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-02-07 DOI: 10.1080/14737140.2026.2625780

Len De Nys, Güleser Güney, Frederique I J Grootjans, Yentl K M Maes, Nele Adriaenssens

{"title":"Body composition and physical activity as predictors of immune-related adverse events in patients undergoing cancer immunotherapy: a systematic review.","authors":"Len De Nys, Güleser Güney, Frederique I J Grootjans, Yentl K M Maes, Nele Adriaenssens","doi":"10.1080/14737140.2026.2625780","DOIUrl":"10.1080/14737140.2026.2625780","url":null,"abstract":"Introduction: Host factors may affect immune-related adverse events (irAE) during immune checkpoint inhibitor (ICI) therapy. We systematically reviewed studies on body composition (BMI, CT/DXA-defined sarcopenia, sarcopenic obesity) and physical activity (PA) in relation to irAE incidence and severity in ICI-treated adults.Methods: PubMed, Embase, Scopus, and Web of Science were searched from inception to 15 December 2024. Eligible studies assessed baseline body composition and/or PA in relation to irAE. Risk of bias was evaluated using the NIH tool and QUIPS. Findings were synthesized using structured narrative methods.Results: Seven studies (2,590 patients) were included. Two large cohorts found overweight/obese patients had higher odds of any-grade irAE (OR = 1.4-1.5); one disease-specific cohort found no association. One CT-based study showed higher irAE risk with sarcopenia (OR = 2.64) and more with sarcopenic obesity (OR = 5.50). Two studies on PA were conflicting: one found higher PA reduced severe irAE risk (OR = 0.19), another found no association.Conclusions: Body composition and PA may help predict irAE in ICI-treated patients. Evidence is low to very low certainty: overweight/obesity may increase toxicity risk, higher PA may lower risk, and evidence for sarcopenia is limited. Standardized prospective studies are needed to confirm these associations.Protocol registration: https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251084119.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"905-916"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146104437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma. Zolbetuximab作为一种胃系定向免疫治疗：cldn18.2阳性胃食管腺癌的机制原理和转化证据

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-18 DOI: 10.1080/14737140.2026.2615855

Kristian Egebjerg, Florian Lordick, Lisa L Liu, Nanna Blücher Dahlgaard, Morten Mau-Sørensen

{"title":"Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma.","authors":"Kristian Egebjerg, Florian Lordick, Lisa L Liu, Nanna Blücher Dahlgaard, Morten Mau-Sørensen","doi":"10.1080/14737140.2026.2615855","DOIUrl":"10.1080/14737140.2026.2615855","url":null,"abstract":"Introduction: Zolbetuximab is a first-in-class monoclonal antibody targeting claudin 18.2 (CLDN18.2) demonstrating clinical benefit in gastroesophageal adenocarcinomas. CLDN18.2 is a gastric lineage-restricted tight-junction protein normally concealed in healthy gastric mucosa but aberrantly exposed on tumor cells due to polarity loss following malignant transformation. Unlike canonical oncogenic drivers, CLDN18.2 has no known oncogenic signaling role and serves as a therapeutic anchor rather than a target for tumor growth inhibition.Areas covered: This review synthesizes preclinical, translational, and clinical evidence to clarify zolbetuximab's mechanism of action. Preclinical studies demonstrated that antitumor efficacy is mediated through immune effector pathways - antibody-dependent cellular cytotoxicity (ADCC) via NK cells and complement-dependent cytotoxicity (CDC). The effect requires high antigen density and is enhanced by chemotherapy-induced CLDN18.2 upregulation. Phase I pharmacodynamic studies confirmed that (i) patients retain intact NK and complement function, (ii) ADCC and CDC are rapidly engaged following infusion, and (iii) activity persists across the dosing interval.Expert opinion: Zolbetuximab exemplifies a novel therapeutic class which can be classified as targeted cytolytic antibodies. Future work should test combinations with checkpoint blockade, refine biomarkers, and define resistance mechanisms.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"817-827"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of health-related social needs on mortality risk in cancer survivors: evidence from 1999-2018 NHANES. 与健康相关的社会需求对癌症幸存者死亡风险的影响：1999-2018年NHANES的证据

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-07-01 Epub Date: 2026-01-28 DOI: 10.1080/14737140.2026.2623054

Pingping Xu, Zhengchuan Niu, Donghao Xu, Yifan Ding, Zhiyuan Zhang

{"title":"Impact of health-related social needs on mortality risk in cancer survivors: evidence from 1999-2018 NHANES.","authors":"Pingping Xu, Zhengchuan Niu, Donghao Xu, Yifan Ding, Zhiyuan Zhang","doi":"10.1080/14737140.2026.2623054","DOIUrl":"10.1080/14737140.2026.2623054","url":null,"abstract":"Background: Cancer survivors experience disproportionate burdens of health-related social needs (HRSNs), yet the mortality implications of cumulative HRSN burden remain poorly characterized.Research design and methods: We analyzed 3643 adult cancer survivors from the 1999-2018 National Health and Nutrition Examination Survey. HRSNs burden was assessed based on eight indicators. Cox proportional hazard models were applied to estimate the associations between cumulative number of unmet HRSNs and all-cause, cardiovascular disease (CVD), and cancer mortality, reporting hazard ratios (HRs) and 95% confidence intervals (CIs).Results: Over a median 85-month follow-up, 1304 (24.99%) participants died, including 433 from cancer and 334 from CVD. Compared to those with 0-1 unmet HRSN, HRs (95% CIs) for participants with 6-8 unmet HRSNs were 4.01 (2.89-5.58) for all-cause mortality, 2.34 (1.08-5.06) for CVD mortality, and 4.00 (2.41-6.64) for cancer mortality. Restricted cubic spline curves found no evidence of non-linear relationships between unmet HRSNs count and all-cause, CVD, and cancer mortality. Associations between HRSN burden and all-cause and cancer mortality were more pronounced in participants under 60 years of age.Conclusion: Cumulative HRSN burden is associated with mortality risk among cancer survivors, particularly younger adults. Routine HRSNs assessment should be integrated into survivorship care to identify high-risk patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"937-946"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0